Purchase this article with an account.
A. Scupola, M. C. Savastano, P. Sasso, B. Falsini, A. M. Minnella, D. Marangoni, A. Mastrocola, G. Zinzanella, S. Petroni, E. Balestrazzi; Microperimetric Evaluation of Myopic Choroidal Neovascularization Treated With Intravitreal Bevacizumab (Avastin). Invest. Ophthalmol. Vis. Sci. 2008;49(13):2679.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effects of intravitreal bevacizumab (IB) in subfoveal choroidal neovascularization secondary to pathological myopia (mCNV) by microperimetry analysis
Ten eyes of 10 patients with mCNV were treated with 1.25 mg IB and evaluated over six months by visual acuity (VA), fundus related perimetry (MP1), optical coherence tomography (OCT), and fluorescein angiography (FA). Five (50%) eyes were treated with a single injection and five (50%) eyes received two injections. Main outcome measures were microperimetry shift of preferred retinal locus (PRL) and macular sensitivity (MS).
In all study eyes, post-injection microperimetric exam revealed a PRL shift towards anatomic fovea. Mean PRL location at baseline was 2.25 degrees (standard error, SE=0.49) from the fovea, with a mean distance reduction of 0.79 degrees (p<0.0001) at 6 months post-injection. Mean sensitivity at baseline was 5.72 dB (SE=0.95) with a mean increase of 2.72 dB (p<0.0001) at 6 months post-injection. The amount of post-injection PRL shift was quantitatively correlated (p < 0.01) with the reduction of foveal thickness.
Results of this pilot trial show significant changes in PRL and MS following IB for mCNV, in agreement with VA, OCT and Fluorescein angiography improvements.
This PDF is available to Subscribers Only